Five Prime Therapeutics Inc.

37.94-0.0300-0.08%Vol 943.63K1Y Perf 1 295.59%
Apr 13th, 2021 16:00 DELAYED
BID37.91 ASK37.98
Open37.96 Previous Close37.97
Pre-Market- After-Market-
 - -%  - -
Target Price
36.71 
Analyst Rating
Moderate Buy 2.43
Potential %
-3.29 
Finscreener Ranking
     41.97
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★★+     55.26
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★+     39.59
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap1.77B 
Earnings Rating
Sell
Price Range Ratio 52W %
97.35 
Earnings Date
6th May 2021

Today's Price Range

37.9437.98

52W Range

2.6138.90

5 Year PE Ratio Range

-8.106.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-0.03%
1 Month
0.61%
3 Months
153.81%
6 Months
540.30%
1 Year
1 295.59%
3 Years
122.05%
5 Years
-18.34%
10 Years
-

TickerPriceChg.Chg.%
FPRX37.94-0.0300-0.08
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.492.58001.01
XOM55.710.21000.38
WFC39.77-1.0000-2.45
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
13.00
13.20
0.14
0.18
-
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
-
-602.40
-578.00
-517.10
-
RevenueValueIndustryS&P 500US Markets
4.76M
0.10
-44.28
-41.52
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.50-0.51-2.00
Q03 2020-0.61-0.74-21.31
Q02 2020-0.70-0.4831.43
Q01 2020-0.68-0.5716.18
Q04 2019-0.97-0.898.25
Q03 2019-0.95-1.03-8.42
Q02 2019-0.86-0.99-15.12
Q01 2019-1.07-1.024.67
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.54-3.85Negative
6/2021 QR-0.474.08Positive
12/2021 FY-2.130.00-
12/2022 FY-1.861.59Positive
Next Report Date6th May 2021
Estimated EPS Next Report-0.54
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume943.63K
Shares Outstanding46.57M
Trades Count5.25K
Dollar Volume36.76M
Avg. Volume2.01M
Avg. Weekly Volume1.08M
Avg. Monthly Volume1.58M
Avg. Quarterly Volume2.18M

Five Prime Therapeutics Inc. (NASDAQ: FPRX) stock closed at 37.97 per share at the end of the most recent trading day (a 0.08% change compared to the prior day closing price) with a volume of 694.39K shares and market capitalization of 1.77B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 87 people. Five Prime Therapeutics Inc. CEO is Thomas Civik.

The one-year performance of Five Prime Therapeutics Inc. stock is 1295.59%, while year-to-date (YTD) performance is 123.22%. FPRX stock has a five-year performance of -18.34%. Its 52-week range is between 2.61 and 38.9, which gives FPRX stock a 52-week price range ratio of 97.35%

Five Prime Therapeutics Inc. currently has a PE ratio of -16.50, a price-to-book (PB) ratio of 6.66, a price-to-sale (PS) ratio of 371.19, a price to cashflow ratio of 4.80, a PEG ratio of 2.32, a ROA of -29.30%, a ROC of -51.96% and a ROE of -39.32%. The company’s profit margin is -%, its EBITDA margin is -578.00%, and its revenue ttm is $4.76 Million , which makes it $0.10 revenue per share.

Of the last four earnings reports from Five Prime Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.54 for the next earnings report. Five Prime Therapeutics Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Five Prime Therapeutics Inc. is Moderate Buy (2.43), with a target price of $36.71, which is -3.29% compared to the current price. The earnings rating for Five Prime Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Five Prime Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Five Prime Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 33.27, ATR14 : 2.32, CCI20 : 131.09, Chaikin Money Flow : -0.10, MACD : 4.82, Money Flow Index : 48.56, ROC : 0.66, RSI : 78.61, STOCH (14,3) : 97.37, STOCH RSI : 0.98, UO : 59.45, Williams %R : -2.63), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Five Prime Therapeutics Inc. in the last 12-months were: David V. Smith (Sold 0 shares of value $0 ), Francis W. Sarena (Sold 0 shares of value $0 ), Helen Collins (Sold 0 shares of value $0 ), William R. Ringo (Option Excercise at a value of $190 369), William R. Ringo (Sold 78 959 shares of value $1 776 577 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (42.86 %)
3 (37.50 %)
3 (33.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (42.86 %)
4 (50.00 %)
5 (55.56 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (14.29 %)
1 (12.50 %)
1 (11.11 %)
Summary RatingModerate Buy
2.43
Moderate Buy
2.50
Hold
2.56

Five Prime Therapeutics Inc.

Five Prime Therapeutics Inc is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. Its is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology. It has the following product in pipeline: Cabiralizumab, FPA150, Bemarituzumab and Immuno-Oncology.

CEO: Thomas Civik

Telephone: +1 415 365-5600

Address: 111 Oyster Point Boulevard, South San Francisco 94080, CA, US

Number of employees: 87

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

52%48%

News

Stocktwits